预防性使用止吐药物联合化疗对乙状结肠癌化疗患者恶心呕吐发生率及程度的影响

The Impact of Prophylactic Use of Antiemetic Drugs Combined with Chemotherapy on the Incidence and Severity of Nausea and Vomiting in Patients with Sigmoid Colon Cancer Undergoing Chemotherapy

摘要: 目的：开展预防性使用止吐药物联合化疗对乙状结肠癌化疗患者恶心呕吐发生率及程度的影响研究。方法：以医院近期收治乙状结肠癌化疗患者为例，随机抽取20名，并获取20名患者书面知情同意后，严格遵循随机对照原则开展研究，均分为对照组(10例)、观察组(10例)，对照组仅进行化疗治疗，观察组基于化疗联合预防性使用止吐药物。比较两组不同方法下，两组患者恶心呕吐次数，总发生率，并对结果进行统计学数据分析。结果：观察组患者比较对照组恶心呕吐次数更少，总发生率更低，两组存在显著差异，且P < 0.05，结果具有统计学意义。结论：基于本次研究临床观察与研究数据显示，预防性使用止吐药物，在减少化疗副作用恶心呕吐的症状上存在显著优势，临床可进一步对此进行研究探讨。

Abstract: Objective: To investigate the impact of prophylactic use of antiemetic drugs combined with chemotherapy on the incidence and severity of nausea and vomiting in patients with sigmoid colon cancer undergoing chemotherapy. Methods: A total of 20 patients with sigmoid colon cancer recently admitted to the hospital were randomly selected. After obtaining written informed consent from all patients, a randomized controlled study was conducted. The patients were equally divided into a control group (10 cases) and an observation group (10 cases). The control group received chemotherapy alone, while the observation group received chemotherapy combined with prophylactic antiemetic drugs. The number of nausea and vomiting episodes and the overall incidence were compared between the two groups, and the results were statistically analyzed. Results: The observation group had fewer episodes of nausea and vomiting and a lower overall incidence compared to the control group. The difference between the two groups was statistically significant (P < 0.05). Conclusion: Based on the clinical observations and research data from this study, prophylactic use of antiemetic drugs demonstrates significant advantages in reducing the side effects of chemotherapy, particularly nausea and vomiting. Further clinical investigation on this approach is warranted.